Opexa Therapeutics (OPXA) – Analyst EPS View
-
Aegis Capital Positive on Opexa Therapeutics (OPXA) Post-Q2; Focus Remains on Abili-T Data
-
Aegis Affirms Opexa Therapeutics (OPXA) at 'Buy'; Abili-T Testing for Tcelna in MS Remains Key Driver
-
Back to OPXA Stock Lookup